Stay updated on CC-486 and MK-3475 in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the CC-486 and MK-3475 in Lung Cancer Clinical Trial page.

Latest updates to the CC-486 and MK-3475 in Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe displayed site revision changed from v3.8.0 to v3.8.1. The study information appears unchanged.SummaryDifference0.0%

- Check8 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the CC-486 and pembrolizumab study, including its terminated status, study design, eligibility criteria, locations, and reported outcomes, instead of a 403 error.SummaryDifference78%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe site footer revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 error.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The clinical trial record still displays a 403 error.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site revision displayed in the footer changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to CC-486 and MK-3475 in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CC-486 and MK-3475 in Lung Cancer Clinical Trial page.